Inflammatory Bowel Disease News

Multimodal intestinal ultrasound performed at 24 weeks can provide “useful information” for predicting endoscopic response at 1 year in patients with active Crohn’s disease initiating treatment with Stelara, according to researchers.

The FDA has granted orphan drug designation to PharmassêtX’s PSX-514, a drug derived from an active component of green tea, for the treatment of pouchitis, according to a company press release.

In this video, Florence-Damilola Odufalu, MD, assistant professor of medicine at the University of Southern California, Keck School of Medicine, discusses family planning, pregnancy and managing inflammatory bowel disease.

Healio spoke with Florence-Damilola Odufalu, MD, assistant professor of medicine at the University of Southern California, Keck School of Medicine, about the future of inflammatory bowel disease and precision medicine.

Hormone replacement therapy was associated with improved disease symptoms, measured by the physician global assessment score, in a cohort of postmenopausal women with inflammatory bowel disease, according to data.

An adalimumab concentration threshold of 12.1 µg/mL “may be a target for therapeutic drug monitoring” to achieve complete fistula healing in perianal fistulizing Crohn’s disease, according to research in Clinical Gastroenterology and Hepatology.

The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, making it the first interleukin-23 specific inhibitor approved for both UC and Crohn’s disease, AbbVie reported.

Marla C. Dubinsky, MD, winner of the 2023 Healio Lifetime Disruptor Award, was first inspired to “disrupt the space” after witnessing patients with inflammatory bowel disease become frustrated with lack of support and access to care.

In this video, Raymond Cross, MD, spoke with Healio about several studies assessing the safety and efficacy of JAK inhibitors in patients with IBD presented at Digestive Disease Week 2024.

Difficult-to-treat psoriatic arthritis was common in a large, real-life cohort, with key risk factors including extensive psoriasis, higher BMI and a history of inflammatory bowel disease, according to data published in Rheumatology.